Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new Omega-3 molecule bypass fat digestion?

NCT ID NCT07771309

Knowledge-focused Sponsor: University of Copenhagen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This trial tests whether a new form of omega-3, called DHA-taurine, is absorbed better than a standard omega-3 supplement when taken without food. Healthy men aged 18 to 30 receive both supplements on separate days, and researchers measure DHA levels in the blood over 8 hours. The goal is to see if DHA-taurine can deliver omega-3s even when normal fat digestion is limited, which could help people with fat absorption issues.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DHA-taurine (a novel omega-3 supplement) compared with DHA ethyl ester (a conventional omega-3 supplement)
What this could lead to
If DHA-taurine is absorbed well without food, it could lead to omega-3 supplements that work for people with fat absorption problems or low-fat diets.
What could go wrong
This is a very small early study in healthy young men, so results may not apply to broader populations. The new molecule may not absorb better than the standard form.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

6 people

The number who actually took part.

Started

Apr 2025

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 30 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male * Healthy * Age between 18 and 30 years * Body mass index between 18.5-25 kg/m2 * Informed consent * Moderate level of physical activity Exclusion Criteria: * Use of fish-oil/omega-3 FA supplements within the last 3 months * Regular tobacco smoking or use of other nicotine-containing products * Allergy or intolerance to ingredients included in the standardised meals * Weekly intake of fish \>350 g (23) * First-degree relatives with diabetes and/or glycated haemoglobin (HbA1c) \>48 mmol/mol, familial hypercholesterolemia/hyperlipidaemia * Anaemia (haemoglobin below 8.3 mmol/L) * Alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) \>2 times upper normal values (Normal values: ALAT \< 70 U/L, ASAT \<45 U/L) * Nephropathy (serum creatinine \>105 μmol/L) and/or albuminuria (\>30 mg/g albumin in urine)) * History of hepatobiliary or gastrointestinal disorder(s) * Any physical or psychological condition, or ongoing medication, that the investigator evaluates would interfere with trial participation, including any acute or chronic illnesses

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Absorption of omega-3 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Absorption of omega-3 Omega-3 fatty acids Pharmacokinetics

Contacts and locations

Locations

  • Department of Biomedical Sciences, University of Copenhagen

    Copenhagen, 2200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.